Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Vectored antibody gene delivery for the prevention or treatment of HIV infection

Vectored antibody gene delivery for the prevention or treatment of HIV infection REVIEW URRENT Vectored antibody gene delivery for the prevention PINION or treatment of HIV infection Cailin E. Deal and Alejandro B. Balazs Purpose of review To discuss recent progress in the use of vectors to produce antibodies in vivo as an alternative form of HIV prophylaxis or therapy. Instead of passive transfer of monoclonal antibody proteins, a transgene encoding an antibody is delivered to cells by the vector, resulting in expression and secretion by the host cell. This review will emphasize adeno-associated virus (AAV)-based strategies and summarize the evidence in support of this strategy as an alternative to traditional vaccines. We will highlight the major findings in the field and discuss the impact that this approach could have on the prevention, treatment and possibly eradication of HIV in patients. Recent findings In this emerging field, the emphasis has been on the use of vectors delivering antibodies as an alternative to the development of an HIV vaccine. However, recent findings suggest that AAV-delivered broadly neutralizing antibodies can suppress HIV replication. As such, a single injection of AAV could mediate long-term antibody expression to act as a long-lived therapeutic in the absence of antiretroviral drugs. Summary Vector-mediated antibody expression can both http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in HIV and Aids Wolters Kluwer Health

Vectored antibody gene delivery for the prevention or treatment of HIV infection

Balazs, Alejandro B.
Current Opinion in HIV and Aids , Volume 10 (3) – May 1, 2015
Download PDF
8 pages

Loading next page...
 
/lp/wolters-kluwer-health/vectored-antibody-gene-delivery-for-the-prevention-or-treatment-of-hiv-35fE8WXz4e

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
1746-630X
eISSN
1746-6318
DOI
10.1097/COH.0000000000000145
pmid
25700206
Publisher site
See Article on Publisher Site

Abstract

REVIEW URRENT Vectored antibody gene delivery for the prevention PINION or treatment of HIV infection Cailin E. Deal and Alejandro B. Balazs Purpose of review To discuss recent progress in the use of vectors to produce antibodies in vivo as an alternative form of HIV prophylaxis or therapy. Instead of passive transfer of monoclonal antibody proteins, a transgene encoding an antibody is delivered to cells by the vector, resulting in expression and secretion by the host cell. This review will emphasize adeno-associated virus (AAV)-based strategies and summarize the evidence in support of this strategy as an alternative to traditional vaccines. We will highlight the major findings in the field and discuss the impact that this approach could have on the prevention, treatment and possibly eradication of HIV in patients. Recent findings In this emerging field, the emphasis has been on the use of vectors delivering antibodies as an alternative to the development of an HIV vaccine. However, recent findings suggest that AAV-delivered broadly neutralizing antibodies can suppress HIV replication. As such, a single injection of AAV could mediate long-term antibody expression to act as a long-lived therapeutic in the absence of antiretroviral drugs. Summary Vector-mediated antibody expression can both

Journal

Current Opinion in HIV and Aids – Wolters Kluwer Health

Published: May 1, 2015

There are no references for this article.